Related references
Note: Only part of the references are listed.Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number
C. Buors et al.
BLOOD CANCER JOURNAL (2012)
Sensitive Detection and Quantification of the JAK2V617F Allele by Real-Time PCR Blocking Wild-Type Amplification by Using a Peptide Nucleic Acid Oligonucleotide
Cornelis J. J. Huijsmans et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Visual screening for JAK2V617F mutation by a disposable dipstick
Jessica K. Konstantou et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2010)
A Real-Time Polymerase Chain Reaction Assay for Rapid, Sensitive, and Specific Quantification of the JAK2V617F Mutation Using a Locked Nucleic Acid-Modified Oligonucleotide
Barbara Denys et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory Evaluation of Screening and Quantitation Methods
Milena Cankovic et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Clinical relevance of JAK2 (V617F) mutant allele burden
Francesco Passamonti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study
Eric Lippert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics
Ayalew Tefferi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
A role for JAK2 mutations in myeloproliferative diseases
Kelly J. Morgani et al.
ANNUAL REVIEW OF MEDICINE (2008)
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
C. Walz et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
A. M. Vannucchi et al.
LEUKEMIA (2007)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
Nicolaus Kroeger et al.
BLOOD (2007)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
JAK2 V617F in myeloid disorders: Molecular diagnostic techniques and their clinical utility - A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
David P. Steensma
JOURNAL OF MOLECULAR DIAGNOSTICS (2006)
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
CHM Jamieson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
AV Jones et al.
BLOOD (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
AV Jones et al.
BLOOD (2005)
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes
DP Steensma et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
The chronic myeloproliferative disorders: Clonality and clinical heterogeneity
JL Spivak
SEMINARS IN HEMATOLOGY (2004)
Share Paper
